Loading this company
Loading this company
Priced within our range of $36.26 to $59.76.A range by design: peer multiples and our researched mid-cycle DCF.
$38.42USD down −$0.41 (−1.06%)
Quoted · Prices are delayed.
Nothing we can cite explains today’s move for this company.
Our range from 2 models, on today’s numbers
$36.26–$59.76
A range by design: peer multiples and our researched mid-cycle DCF.
What the price needs: revenue growth of 1.3%/yr for 5 years (our model assumes 1.0%).
Led by peer multiples (P/E, EV/EBITDA, P/S) · Cyclical business
Delayed price used by the model $39.34Prices are delayed.
Our forward range over 12 months is part of Pro. See plans
Analysts’ mean target
$45.73 across 12 analysts
The high and low of the analyst range is part of Pro. See plans
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. It operates in the Drug Manufacturers - General industry (Healthcare sector), headquartered in Denmark. The company employs roughly 66,700 people.
Revenue: Obesity and Diabetes care 94% · Rare disease 6%
Prices are delayed. The feed does not say when these figures were taken.
No filings or corporate activity on file in the recent window.
No recent headlines we can cite for this company.
No insider filings for this company in the recent window.
Not investment advice. TickerWorth Score is a model output.
The score, the fair value and the reverse DCF are free on every company. Pro lets you change growth, margin and the discount rate yourself, see every valuation lens and its working, and download the model. Start a 7-day free trial — a card is required and you can cancel any time before it ends. $99 a year, or $14.99 monthly.